Clinical trials: AMD - Age-Related Macular Degeneration
Age-Related Macular Degeneration
Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study
Study: observational prospective clinical study. Study population: Subjects over 55 years old with drusen secondary to intermediate AMD. Recruitment: at the Medical Retinal Consultation from the Ophthalmology Department of CHULC.
- Trial name
- Imaging4iAMD (NCT06355830)
- Testing
- Orthoptic assessment (Outcome measure)
- Where
- Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade Nova de Lisboa
Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO)
High-throughput Large-model-based AI-assisted Diagnosis Using OCT
This observational study aims to establish key technologies for high-throughput, large-model-based AI-assisted diagnosis using optical coherence tomography (OCT) and OCT angiography (OCTA).
- Conditions
- Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO), Age-Related Macular Degeneration (AMD), Pathologic Myopia
- Trial name
- NCT07249307
- Testing
- No intervention
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
nAMD
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
- Trial name
- NCT06672536
- Testing
- SCT520FF, EYLEA 2 MG
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sinocelltech Ltd.
Geographic Atrophy, Dry Age Related Macular Degeneration
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
- Trial name
- NCT00429936
- Testing
- Fenretinide
- Volunteers
- 245 people
- Sponsor
- Sirion Therapeutics, Inc.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting…
- Trial name
- NCT04480463
- Testing
- SCD411, Aflibercept
- Where
- 130 sites in United States, Australia and 12 more
- Volunteers
- 576 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Neovascular Age Related Macular Degeneration
Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
This study is designed to evaluate the effect of Visudyne® combination therapy (Visudyne® [verteporfin for injection] and Lucentis™) on visual acuity outcomes.
- Trial name
- Luvi (NCT00574093)
- Testing
- Ranibizumab; Verteporfin
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Peripheral Retinal Degenerations, Age Related Macular Degeneration Polymorphisms
The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular Degeneration
Purpose: To examine the genotypes associated with the peripheral retinal phenotypic features in patients with age-related macular degeneration documented with wide-field imaging. Design: Clinic-based case series study in Croatia.
- Trial name
- NCT03492853
- Testing
- DNA extraction and sequencing
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- University Hospital Sestre Milosrdnice
Macular Degeneration
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related…
- Trial name
- NCT00041483
- Testing
- Anecortave Acetate 15 mg sterile suspension, Photodynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 530 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.
- Trial name
- NCT01678872
- Testing
- RetinoStat
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Oxford BioMedica
Exudative Age-related Macular Degeneration
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries.
- Trial name
- NCT01404845
- Testing
- Nutrof Total, food supplement without Lutein and Zeaxanthin
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Affordance
Geographic Atrophy, Age-Related Macular Degeneration
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration.
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration, AMD
- Trial name
- NCT00306488
- Testing
- OT-551 antioxidant eye drop
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Macular Degeneration
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Risk factors for Age-related Macular Degeneration (AMD) involves genetic variations in the alternative pathway of complement inhibitor factor H. The complement system is part of the innate and adaptive immune system.
- Trial name
- CFH&AMD (NCT01115231)
- Where
- 2 sites in United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration
Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in…
- Conditions
- Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- LUMINOUS (NCT01318941)
- Testing
- Ranibizumab
- Where
- 463 sites in Argentina, Australia and 41 more
- Volunteers
- 30,490 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Cataract
Age-Related Eye Disease Study (AREDS) Follow-Up
This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts.
- Trial name
- NCT00594672
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Ocular Safety and Usability Study for FYB201 PFS
The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT06708624
- Testing
- FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Formycon AG
Age-related Macular Degeneration
Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Because a possible synergism of radiation and inhibitors of vascular endothelial growth factor has been shown in cancer patients and patients with wet macular degeneration, this pilot study is being conducted to determine whether…
- Trial name
- NCT00517010
- Testing
- Proton beam irradiation and ranibizumab
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Wet Age Related Macular Degeneration, wAMD
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
- Trial name
- wAMD (NCT06683742)
- Testing
- EYP-1901, Aflibercept (2.0 mg)
- Where
- 113 sites in United States, Brazil and 8 more
- Volunteers
- 400 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Neovascular Age-related Macular Degeneration
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
- Trial name
- Sightspire (NCT06847542)
- Testing
- Susvimo PDS Implant, Ranibizumab
- Where
- 61 sites in Austria, Czechia and 11 more
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Dry Macular Degeneration
Non Exudative AMD Imaged With SS-OCT- Extension
The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and…
- Trial name
- BIRC-02 (NCT04469140)
- Testing
- SS-OCT imaging
- Where
- 5 sites in United States, Australia
- Volunteers
- 450 people
- Sponsor
- Boston Image Reading Center
Dry Age-related Macular Degeneration, Macular Degeneration
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Trial name
- NCT03894020
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 83 people
- Sponsor
- Gyroscope Therapeutics Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.